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Abstract
Background: Patients with end-stage renal disease (ESRD) exhibit a premature aging phenotype of the immune
system. Nevertheless, the etiology and impact of these changes in ESRD patients remain unknown.
Results: Compared to healthy individuals, ESRD patients exhibit accelerated immunosenescence in both T cell and
monocyte compartments, characterized by a dramatic reduction in naïve CD4+ and CD8+ T cell numbers but
increase in CD8+ TEMRA cell and proinflammatory monocyte numbers. Notably, within ESRD patients, aging-related
immune changes positively correlated not only with increasing age but also with longer dialysis vintage. In
multivariable-adjusted logistic regression models, the combination of high terminally differentiated CD8+ T cell
level and high intermediate monocyte level, as a composite predictive immunophenotype, was independently
associated with prevalent coronary artery disease as well as cardiovascular disease, after adjustment for age, sex,
systemic inflammation and presence of diabetes. Levels of terminally differentiated CD8+ T cells also positively
correlated with the level of uremic toxin p-cresyl sulfate.
Conclusions: Aging-associated adaptive and innate immune changes are aggravated in ESRD and are associated
with cardiovascular diseases. For the first time, our study demonstrates the potential link between
immunosenescence in ESRD and duration of exposure to the uremic milieu.
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Background
Patients with end-stage renal disease (ESRD) exhibit
many physiological changes reminiscent of accelerated
aging processes and have an increased mortality and sus-
ceptibility to diseases when compared to chronological
age-matched individuals [1]. Impaired physical functions,
muscle wasting, cognitive function decline, accelerated
vascular disease and increased risks of death are among
the many aging-related complications increased in
frequency in ESRD [2]. The immune system of ESRD pa-
tients also exhibits significant changes from that of healthy
individuals. For example, while a low grade-inflammation
can be observed during normal aging [3], it is significantly
enhanced by uremia [4]. Accompanying low-grade inflam-
mation, immune cells develop different phenotypic
markers and functions during normal aging. These
changes are are collectively called “immunosenescence”
and are considered to contribute to various aging-related
morbidities, including increased risks for infectious events
and cardiovascular diseases [5–7].
During normal aging, lymphocytes and monocytes ex-
perience dramatic changes. The subset distribution in
the CD8+ T cell compartment is different between young
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and old people; with progressive terminal differentiation [8],
loss of co-stimulatory molecules, shortening of telomeres
and impaired response toward infectious pathogens and vac-
cinations [9, 10] occur during aging. CD4+ T cells also ex-
hibit aging-related changes. For example, naïve CD4 T cells
from aged animals show reduced IL-2 production, prolifera-
tion, helper function, effector generation and memory func-
tion [11]. Premature aging of the T cell compartment has
been observed in ESRD patients, characterized by decreased
thymic output of naïve cells and increased susceptibility to-
ward apoptosis [12]. We had previously reported that higher
levels of CD4+CD28- cells can be found in ESRD patients
[13] and CD4+ T cells activation is affected in ESRD patients
in an age-dependent manner [14]. Recently, it has been re-
ported that elderly kidney transplant patients also exhibit
more advanced T cell differentiation compared to younger
patients [15]. Besides lymphocytes, CD14++CD16+ inter-
mediate monocytes as well as the CD14+CD16++
non-classical monocytes also increase in numbers during
aging [16] and are further increased in ESRD patients [17].
CD14++CD16+ intermediate monocytes are of particular
interest because these cells produce high levels of TNF-α
and IL-6 upon activation and are involved in many infectious
and pathogenic inflammatory diseases [18, 19].
As a result, enhanced aging-related immune changes
can be considered as one characteristic of the premature
aging phenotype of renal failure. However, it remains
unclear how mechanistically the immune system suffers
from these enhanced aging-related changes in renal fail-
ure patients. In addition, previous studies attempted to
characterize the immune system of ESRD patients were
frequently based on small numbers of patient and did
not include both monocyte and lymphocyte panels at
the same time. We hypothesize that if ESRD patients
have accelerated aging, exposure of immune cells to the
uremic milieu will also have an impact on immunose-
nescence, independent of chronological age. In addition,
profiling both adaptive and innate immune subsets
should be performed simultaneously to better under-
stand the overall effects of uremia on aging-related im-
mune responses.
We thus initiated the Immunity in ESRD study, or the
iESRD study to comprehensively characterize the im-
mune changes in ESRD. The iESRD study is an on-going
longitudinal cohort study with the ultimate goal to in-
vestigate if immune changes are associated with
long-term clinical outcomes. Here, we present the find-
ings from analyzing the baseline data of this study based
on 412 hemodialysis patients.
Methods
Study participants
The immunity in ESRD study (iESRD) is a multicenter
study which recruited ESRD patients undergoing regular
hemodialysis with age > 20 years at two academic teach-
ing hospitals in Taiwan: the Far Eastern Memorial Hos-
pital and the National Taiwan University Hospital Yun
Lin branch. A total 432 patients signed informed con-
sent and were screened for eligibility. Those with recent
hospitalization within three months, active infection, in-
complete blood test results or poor blood samples qual-
ity were excluded, making only 412 patients included in
the final study (198 from Far Eastern Memorial Hospital
and 214 from National Taiwan University Hospital).
CMV serostatus in all individuals were determined
using the Roche Elecsys assay. All methods were carried
out in accordance with relevant guidelines and regula-
tions. All experimental protocols were approved by the
Research Ethics Committee of both institutions (FEMH
103084-E and NTUYL 201511092 RINA). Informed
consent was obtained from all participants and/or their
legal guardians.
Data collection
Biochemical data were collected on the same day of per-
ipheral blood mononuclear cells (PBMCs) sampling.
Blood samples were collected before start of a
hemodialysis session in the middle of week. Diagnosis of
coronary artery disease (CAD) was defined as either 1)
> 50% stenosis of at least one coronary artery on coron-
ary angiography or 2) documented reperfusion defect on
stressed nuclear medicine scan. Peripheral arterial occlu-
sive disease and stroke were based on medical chart re-
view. Cardiovascular disease (CVD) is defined by the
medical history of either CAD, peripheral arterial occlu-
sive disease or stroke.
T cell and monocyte differentiation panel
On the day of blood sampling, PBMCs were isolated by
Ficoll-Paque PLUS gradient centrifugation following the
manufacturer’s protocol (GE Healthcare). Freshly isolated
PBMCs were immediately stained with antibody cocktails
and processed for flow cytometer reading and analysis as
previously described [12, 17]. The gating strategy is shown in
Additional file 1: Figure S1. Briefly, singlets were identified
by forward scatter area and height. Lymphocytes were subse-
quently gated by forward and side scatter characteristics, and
anti-CD3-AF700 (clone UCHT1, Biolegend) was used to
identify CD3+ T cells. CD4+ and CD8+ T cells, determined
by anti-CD4-PerCP-Cy5.5 (clone OKT4, Biolegend) and
anti-CD8-APC-Cy7 (clone SK1, Biolegend), were further
analyzed by their surface anti-CCR7-APC (clone G043H7,
Biolegend) and anti-CD45RA-Alexa488 (clone HI100, Biole-
gend) expression to separate into the CCR7+CD45RA+
TNAIVE subset, the CCR7+CD45RA-TCM subset, the
CCR7-CD45RA-TEM subset and the CCR7-CD45RA
+TEMRA subset. CD28-PE-Cy5 (clone CD28.2, eBioscience)
and CD95-PE (clone DX2, eBioscience) were used to further
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define stem cell memory T cells (Tscm) from the TNAIVE
subset.
Anti-CD86-PE (clone IT2.2, eBioscience) was used to
gate the CD86+ monocytes. By anti-CD14-FITC (clone
M5E2, Biolegend) and anti-CD16-APC (clone 3G8,
eBioscience), monocytes were further classified as clas-
sical (Mon1, CD14++CD16-), intermediate (Mon2,
CD14++CD16+), and non-classical (Mon3, CD14 +
CD16++) monocytes. We used a clinical complete blood
count (CBC) analyzer Beckman Coulter LH 780 to de-
termine the absolute lymphocyte and monocyte counts
for each sample and subset cell numbers were subse-
quently enumerated. All the experiments were per-
formed in Far Eastern Memorial Hospital and analyzed
using a Beckman Coulter MoFlo™-XDP multicolor flow
cytometer.
Measurements of uremic toxin p-cresyl sulfate and
indoxyl sulfate
Serum p-cresyl sulfate (PCS) and indoxyl sulfate (IS)
were measured with liquid chromatography-mass spec-
trometry (4000 QTRAP, USA). In brief, serum samples
were prepared and deproteinised by heat denaturation.
The concentrations of IS and PCS were measured in
serum ultrafiltrates, obtained by using Microcon YM-30
separators (Millipore, Billerica, MA, USA). HPLC was
performed at room temperature using a dC18 column
(3.0 × 50 mm, Atlantis, Waters). The sensitivity of this
assay was 1 μg/L for PCS and 1 μg/L for IS.
Statistical analyses
Baseline characteristics were described as mean ± stand-
ard deviation for continuous variables, and frequency for
categorical variables. Spearman’s correlation was applied
to evaluate the correlation of immunological markers
with age and biochemical data. Partial regression plots
were used to analyze the relationships between immune
cell subset percentages and age adjusting for dialysis vin-
tage, or between immune cell subset percentages and
dialysis vintage adjusting for age. CAD and CVD were
analyzed separately as in most cardiovascular outcome
studies.
The R corrplot package was used to draw the correlo-
gram to visualize the relationships between immune cell
subsets (Freely available at http://www.sthda.com/eng-
lish/wiki/visualize-correlation-matrix-using-correlo-
gram). A p value of more than 0.05 was considered
insignificant and only significant results are shown on
the correlogram.
Logistic regression models, adjusted for age, gender, al-
bumin, hemoglobin, diabetes mellitus, and hs-CRP, were
used to evaluate the independent relationship between
immunophenotype and the presence of CAD or CVD.
All statistical tests were two-tailed, and a p value of less
than 0.05 was considered be significant. The statistical
analyses were performed with STATA version 13.1.
Results
Aggravated aging-related immune changes in ESRD
patients
First, we compared the immune cell subsets in the per-
ipheral blood between 412 ESRD patients and 57
age-matched healthy individuals using multicolor flow
cytometry (representative staining, Additional file 1:
Figure S1). The demographic and biochemical data of
the iESRD participants are summarized in Table 1. Main
causes of ESRD were diabetes (37.3%), chronic glomer-
ulonephritis (27.6%), hypertension (14.3%) and others
(20.8%). Because cytomegalovirus (CMV) infection pro-
foundly affects human immune system homeostasis, we
first tested CMV seropositivity frequency among partici-
pants. All healthy individuals (n = 57; 100% CMV sero-
positive) were CMV seropositive and only 4 out of 412
ESRD patients were seronegative for CMV (99% sero-
positive). Despite the majority of our study samples was
CMV seropositive, we detected many immune subsets
differences between healthy versus ESRD (Table 2). For
both CD4+ and CD8+ T cells, ESRD patients demon-
strated lower percentages of TNAIVE cells but increased
percentages of memory stem TSCM cells, which are the
considered to be the least differentiated memory T cells
in humans and plays an important role in immune pro-
tection upon pathogen rechallenge [20]. Interestingly,
these antigen-experienced, naïve phenotype T cells re-
cently were reported to increase during aging [21]. CD8
+ Effector memory TEM and terminally differentiated
TEMRA cells, both memory T cells with higher levels of
differentiation, were increased in percentages in ESRD
patients. Besides these distributional changes, ESRD
Table 1 Demographic data of iESRD participants
Variable Mean (SD)
Age (years) 61.7 (12.2)
Male (%) 50.7
Diabetes (%) 44.6
Malignancy (%) 12.1
Dialysis vintage (years) 6.2 (5.1)
Albumin (g/dL) 4.0 (0.4)
Hemoglobin (g/dL) 10.9 (1.4)
T-cholesterol (mg/dL) 152.2 (37.3)
Triglyceride (mg/dL) 147.1 (95.4)
intact-PTH (pg/mL) 374.5 (423.6)
Calcium (mg/dL) 9.3 (0.8)
Phosphate (mg/dL) 4.9 (1.4)
Kt/V (Gotch) 1.4 (0.2)
The complete demographic data of 412 iESRD participants is shown
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patients exhibit a dramatic 40–50% reduction in CD4+
and CD8+ naïve T cell numbers and especially have a
significant increase in their CD8+ TEMRA cell numbers.
For CD4+ T cells, although percentages of TEM and TEMRA
subsets were not significantly increased, the absolute cell
number of TEM cells was increased in ESRD patients.
Significant differences in the monocyte differenti-
ation status were also found (Table 2). ESRD patients
exhibited higher percentages of intermediate and
non-classical monocytes and lower percentages of
classical monocytes in their peripheral blood. In absolute
cell number terms, the intermediate and non-classical
monocytes were both significantly increased. Similar to
TEMRA cells, levels of intermediate monocytes and
non-classical monocytes are known to increase during
aging [16]. Overall, our observations confirmed that many
immunological changes observed in ESRD are reminiscent
of immunosenescence observed during normal aging.
We next tested whether T cell compartment changes
and monocyte compartment changes are related. As
shown in Additional file 1: Figure S2, we performed cor-
relogram analyses in both healthy and ESRD individuals
using either cell type percentage or absolute cell num-
bers. We found that monocyte subset distribution and T
cell differentiation are not significantly correlated, but
cells of the same lineage tend to be significantly corre-
lated in absolute number.
Dialysis vintage positively associates with
immunosenescence
Although ESRD patients clearly exhibit aggravated im-
mune aging, the etiology of aggravated immune aging
remains unclear. We hypothesize, if the uremia milieu
affects immune cell homeostasis, duration of ESRD or
dialysis treatment (dialysis vintage years) should have a
significant impact on the severity of observed aging
phenotype, independent from the effect of age. We next
interrogated the relationship between percentage of each
immune cell subset with age and dialysis vintage in
multivariable-adjusted regression models. The complete
regression analysis results are shown in Table 3 and key
representative plots are shown in Fig. 1. Because longer
dialysis vintage was associated with the progressive de-
crease in total T cell counts (significant for both CD4+
and CD8+ T cells, data not shown), for this analysis we
used subset percentages to reflect premature aging of
each cell compartment instead of absolute cell counts.
As shown in Table 3, age profoundly affected the T cell
differentiation status by decreasing the percentage of
TNAIVE cells and increasing the percentage of TEM and
TEMRA cells. Both CD4+ and CD8+ TNAIVE cells de-
crease in percentage with aging, but effects of age on
TEMRA cells were more pronounced in the CD8+ com-
partment than CD4+ cells. Consistent with a previous
study made in non-renal failure population [16], we also
found that age positively associated with the percentage
of intermediate monocytes. When we further adjusted
etiology of ESRD in the model, the relationships between
age and immune cell subsets did not change (data not
shown). Longer dialysis vintage years robustly associated
Table 2 Comparisons of immune cell subsets between ESRD
and controls
Cell subset percentage Healthy (57) ESRD (412) P value
CD4+ T cells 62.8 (10.3) 56.8 (13.3)↓ 0.001*
Naïve T cells 41.6 (15.6) 28.5 (12.9)↓ < 0.001*
Stem Memory T cells 3.18 (2.01) 7.50 (6.24)↑ < 0.001*
Central Memory T cells 30.7 (9.6) 41.6 (11.1)↑ < 0.001*
Effector Memory T cells 27.0 (14.7) 28.3 (12.9) 0.47
Terminally Differentiated T cells 1.80 (2.24) 2.36 (2.72) 0.13
CD8+ T cells 26.5 (8.97) 29.2 (10.1) 0.051
Naïve T cells 32.9 (16.6) 21.8 (16.1)↓ < 0.001*
Stem Memory T cells 4.78 (5.26) 7.66 (6.20)↑ 0.002*
Central Memory T cells 6.30 (3.58) 7.02 (7.91) 0.50
Effector Memory T cells 29.1 (11.7) 34.1 (16.6)↑ 0.023*
Terminally Differentiated T cells 32.9 (14.4) 38.1 (16.7)↑ 0.025*
Monocytes
Classical Monocytes 64.1 (12.7) 56.9 (11.7)↓ < 0.001*
Intermediate Monocytes 6.25 (4.91) 10.1 (6.55)↑ < 0.001*
Non-Classical Monocytes 14.1 (10.8) 19.9 (9.7)↑ < 0.001*
Absolute cell number Healthy (57) ESRD (412) P value
CD4+ T cells 530 (307) 523 (232)↓ 0.02*
Naïve T cells 247 (199) 164 (112)↓ < 0.001*
Stem Memory T cells 17.2 (15.5) 11.5 (9.1)↓ < 0.001*
Central Memory T cells 188 (114) 229 (116) 0.65
Effector Memory T cells 89.0 (49.5) 120 (86.4)↑ 0.006*
Terminally Differentiated T cells 5.76 (7.59) 9.25 (11.7) 0.10
CD8+ T cells 277 (270) 275 (180)↓ 0.012*
Naïve T cells 103 (97.7) 54.5 (61.9)↓ < 0.001*
Stem Memory T cells 13.7 (17.6) 4.63 (5.50)↓ < 0.001*
Central Memory T cells 11.6 (9.22) 12.1 (13.9) 0.47
Effector Memory T cells 92.9 (58.0) 102 (83.6) 0.26
Terminally Differentiated T cells 70.2 (53.9) 105 (95.2)↑ 0.013*
Monocytes
Classical Monocytes 248 (91.2) 264 (141) 0.13
Intermediate Monocytes 19.2 (21.9) 40.3 (33.9)↑ 0.001*
Non-Classical Monocytes 18.4 (12.0) 56.3 (38.2)↑ < 0.001*
Percentages and absolute numbers (per μl blood) of naïve (TNAIVE), stem cell
memory (TSCM), central memory (TCM), effector memory (TEM), terminally
differentiated (TEMRA) subsets and three monocyte subsets (classical
monocytes, intermediate monocytes, non-classical monocytes) were shown as
mean (SD) and were compared between healthy controls and ESRD patients.
The inter-group differences were analyzed by Student’s t-test
*P value < 0.05
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with higher percentages of CD8+ TEMRA cells (β = 0.47,
p = 0.002). Importantly, dialysis vintage also positively
associated with percentages of intermediate monocytes
and negatively associated with the percentages of clas-
sical monocytes. To further confirm the effects of dialysis
vintage on immune changes, ESRD patients were sepa-
rated into tertiles based on vintage years for trend analysis
and were also analyzed by robust regression to eliminate
the concern of outliers (Additional file 1: Table S1).
CD4+ CD28null cells are important aging-related T cell
subset that had been reported to increase during aging.
Although CD4+CD28null cells were also increased in dia-
lysis patients, neither percentages nor absolute counts of
CD4+CD28null cells in dialysis patients were correlated
with dialysis vintage (data not shown). Overall, the dialysis
vintage, after statistical adjustment for age, significantly
associated with both immunosenescent T cell differenti-
ation (especially in CD8+ T cells) and higher levels of
intermediate monocytes.
Aging-related immune changes correlate with
cardiovascular risk factors and systemic inflammation
It is well-known that ESRD patients exhibit a dramatic
increased risk for cardiovascular disease when compared
to age-matched healthy individuals [22]. In the literature,
inflammation is responsible for increased risk of athero-
sclerotic diseases and mortality in ESRD because ESRD
patients also exhibit high level of chronic inflammation
[23, 24]. Since immunosenescence contributes to athero-
sclerotic diseases in the elderly without renal diseases
[25], we studied the correlation between parameters of
immunosenescence with traditional as well as
non-traditional cardiovascular risk factors in the iESRD
cohort. We selected CD8+ TNAIVE, CD8+ TEMRA and
intermediate monocytes as key immunosenescence pa-
rameters to perform further analysis in the current study
because both adaptive and innate immunity were impli-
cated in previous studies on atherosclerotic vascular dis-
eases [26] and these subsets were closely associated with
age and/or dialysis vintage. As shown in Additional file 1:
Table S2, these immune changes were associated with
traditional and non-traditional cardiovascular risk factors.
Most importantly, systemic inflammation as measured by
high-sensitivity C-reactive protein was associated with de-
creased CD8+ TNAIVE and increase in intermediate mono-
cyte numbers. The presence of diabetes, another important
cardiovascular risk factor, has little impact on the extent of
immunosenescence (Additional file 1: Table S3).
ESRD patients with concurrent cardiovascular disease
display more severe immunosenescence
To test the impact of aging-related immune changes on
cardiovascular health, percentages and cell numbers of
CD8+ TNAIVE, CD8+ TEMRA cells and intermediate
monocytes were further compared between patients with
and without coronary artery disease (CAD) and between
patients with and without cardiovascular disease (CVD).
Among 412 patients, 106 patients had history of coron-
ary artery disease determined by history of myocardial
infarction, positive coronary angiography or positive
thallium scan; 132 patients had cardiovascular disease
defined by the history of either coronary artery disease
as defined in the method section, stroke, or peripheral
arterial occlusive disease. As shown in Additional file 1:
Table S4, patients with CAD or CVD had lower percent-
ages of CD8+ naive T cells and higher percentages of
CD8+ TEMRA cells. Patients with CVD also had signifi-
cant higher percentages of intermediate monocytes.
The high-CD8+TEMRA/high-intermediate monocyte
immunophenotype independently associates with
existing cardiovascular diseases
Although patients with concurrent cardiovascular dis-
ease had higher percentages of CD8+ TEMRA cells and
CD14++CD16+ intermediate monocytes in their periph-
eral blood, the differences between groups were relatively
small regarding a given immune subset. These findings
prompted us to create a composite immunophenotype
based on both cell subsets. To date, no study has studied
Table 3 Independent effects of age and dialysis vintage on
immune cell aging
Cell Subset (percentage) Age Dialysis Vintage
β P value β P value
CD4+ T cells
Naïve T cells −0.22 < 0.001* 0.20 0.095
Stem Memory T cells 0.08 0.029* 0.03 0.72
Central Memory T cells −0.05 0.24 −0.60 < 0.001*
Effector Memory T cells 0.26 < 0.001* 0.41 0.001*
Terminally Differentiated T cells 0.02 0.12 0.02 0.46
CD8+ T cells
Naïve T cells −0.56 < 0.001* 0.14 0.31
Stem Memory T cells 0.12 0.002* 0.001 0.91
Central Memory T cells −0.01 0.61 0.11 0.16
Effector Memory T cells 0.16 0.014* −0.67 < 0.001*
Terminally Differentiated T cells 0.42 < 0.001* 0.47 0.002*
Monocytes
Classical Monocytes 0.02 0.72 −0.32 0.005*
Intermediate Monocytes −0.03 0.21 0.27 < 0.001*
Non-Classical Monocytes −0.02 0.64 0.06 0.56
To separate the effects of age from dialysis vintage on immune changes, we
tested the independent effects of age and dialysis vintage on cell subset
percentages. In a multivariable-adjusted regression model (using subset
percentage as the independent variable), the independent associations
between immune cell percentage and age as well as the independent
associations between immune cell percentage and vintage are shown
*P value < 0.05
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both adaptive and innate immune cells simultaneously to
investigate whether aging-related immune changes in
ESRD patients (or even individuals with normal renal
function) are related to atherosclerotic complications. To
characterize a clinically useful phenotype based on both
cell types, we tested the use of medium-split of each vari-
able and defined immunophenotypes based on expression
levels of CD8+ TEMRA and intermediate monocyte. We
found that all the iESRD participants can be separated
into four groups: high CD8+ TEMRA/high intermediate
monocytes, high CD8+ TEMRA/low intermediate mono-
cytes, low CD8+ TEMRA/high intermediate monocytes and
the low CD8+ TEMRA/low intermediate monocytes. We
then tested the independent associations of immunophe-
notypes with the concomitant presence of CAD and CVD.
We found that the “high CD8+ TEMRA/high intermediate
monocyte” phenotype is independently associated with
the presence of CAD and CVD (Table 4). We performed
the likelihood ratio test to compare models with and with-
out immunophenotype in the presence of age, DM, CRP
and Hb, and the result was significant (p value = 0.0137).
This suggests that immunophenotype as a whole results
in a statistically significant improvement in model fit.
When cell percentages instead of cell numbers were
used in the model, the associations between immuno-
phenotype and CAD or CVD remains statistically signifi-
cant (Additional file 1: Table S5).
Uremic toxin p-cresyl sulfate positively correlated with
levels of CD8+ TEMRA cells
In renal failure patients, retention of uremic toxins is a
key mechanism underlying the generation of oxidative
Fig. 1 Independent associations between immune cell percentages with age and dialysis vintage. Scatter plots and regression lines
demonstrated the relationship between immune cell differentiations with age or dialysis vintage in ESRD patients. Since dialysis vintage
potentially modulates the effects of age on immunophenotype, we used partial regression plots to show the relationship between immune cell
subset percentage and age adjusting for dialysis vintage, or between immune subset percentage and dialysis vintage adjusting for age. When
indicated, the Y axis presents residuals from regressing immune cell subset percentage against dialysis vintage or age while the X axis presents
residuals from regressing age against dialysis vintage or dialysis vintage against age. For presentation, the axes were labeled as they are instead
of e(age|X) or e(vintage|X)
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stress and inflammation [27]. Others and our previous
study also indicated that higher levels of uremic toxins
in ESRD patients were related to atherosclerotic compli-
cations and mortality [28, 29]. Because aging-related im-
mune changes positively associated with dialysis vintage,
we were curious about the relationships between uremic
toxins with the level of CD8+ TEMRA and intermediate
monocytes. We measured two major uremic toxins,
p-cresyl sulfate and indoxyl sulfate, in 100 iESRD partici-
pants. As shown in Table 5, we found that levels of
uremic toxin p-cresyl sulfate significantly correlated with
higher levels of CD8+ TEMRA cells in both relative per-
centage and absolute cell number terms. Nevertheless,
levels of indoxyl sulfate were not associated with the
accumulation of CD8+ TEMRA cells, and levels of uremic
toxin were not associated with levels of intermediate
monocytes (data not shown).
Discussion
The immunity in ESRD, or “iESRD study” was designed
with the goal of identifying biomarkers that can accur-
ately assess the health status of ESRD patients undergo-
ing hemodialysis and of investigating the potential
mechanism underlying the aggravated aging-related im-
mune changes that may ultimately also apply to the gen-
eral population. A longitudinal follow-up of the cohort
participants is currently being performed to analyze if
immune status can predict patients’ survival and if these
immune changes will evolve over-time.
The baseline analysis found both adaptive and innate
immune subset distribution dramatically changed in
ESRD patients compared with healthy individuals.
Aging-related changes of lymphocytes and monocytes
also positively associate with dialysis vintage and other
cardiovascular risk factors in ESRD patients. In the
current study, we identified the positive association be-
tween these changes and systemic inflammation, and
identified a combinatorial aging-related immunopheno-
type is associated with prevalent atherosclerotic cardio-
vascular disease in ESRD independently from systemic
inflammation. The odds ratio of patients with the high
CD8+ TEMRA and high intermediate monocyte immuno-
phenotype for CAD and CVD is higher than every
1 mg/dL increase in high-sensitivity CRP and is in a
range close to diabetes. Thus, these findings suggest that
aggravated immunosenescence significantly impacts on
ESRD patients’ health.
Our study found both CD4+ and CD8+ T cells differen-
tiations are dramatically enhanced in ESRD patients.
Compared to healthy donors, ESRD patients have much
fewer naïve T cells but at the same time, higher percentage
of memory T cells with advanced differentiation-especially
CD8+ TEMRA cells. Overall, enhanced immunosenescence
is more evident in CD8+ T cells than CD4+ T cells.
Consistent with most published studies, CD4+ T cells tend
to be less affected by aging than CD8+ T cells [30]. Com-
pared to CD8+ T cells, naïve CD4+ T cells maintain their
absolute cell numbers and memory CD4+ T cells maintain
a highly diverse T cell receptor repertoire without signifi-
cant clonal expansion during aging. However, as recently
reviewed by Goronzy et al. [31], it remains largely
unknown why CD4+ T cells are less susceptible to aging.
While a decrease in naïve T cells potentially affects an in-
dividual’s response toward new infections and vaccinations
[30], memory T cells expressing cytotoxic or terminal
differentiation features are increasingly implicated in the
pathogenesis of atherosclerotic disease and inflammation
[26, 32] although many studies are observational so far.
Table 4 A combinatorial aging-associated immunophenotype
independently associates with coronary artery disease and
cardiovascular disease
OR (95% CI) P value
Variables in model (independent variable: CAD)
Immunophenotype
High CD8+ TEMRA High MonINT 2.40 (1.18–4.90) 0.016*
High CD8+ TEMRA Low MonINT 1.56 (0.74–3.28) 0.24
Low CD8+ TEMRA High MonINT 1.01 (0.46–2.16) 0.99
Low CD8+ TEMRA Low MonINT 1.00
Age 1.03 (1.01–1.06) 0.003*
Gender (Male) 1.28 (0.79–2.08) 0.31
Diabetes 3.26 (1.99–5.33) < 0.001*
Albumin (g/dL) 1.21 (0.56–2.21) 0.62
hs-CRP (mg/dL) 1.49 (1.17–1.89) 0.001*
Hemoglobin (g/dL) 1.10 (0.93–1.30) 0.28
Variables in model (independent variable: CVD)
Immunosenescence
High CD8+ TEMRA High MonINT 2.39 (1.21–4.70) 0.012*
High CD8+ TEMRA Low MonINT 1.93 (0.97–3.84) 0.06
Low CD8+ TEMRA High MonINT 1.47 (0.72–2.97) 0.29
Low CD8+ TEMRA Low MonINT 1.00
Age 1.03 (1.01–1.06) 0.001*
Gender (Male) 1.28 (0.81–2.01) 0.29
Diabetes 2.92 (1.86–4.60) < 0.001*
Albumin (g/dL) 1.03 (0.51–2.08) 0.93
hs-CRP (mg/dL) 1.40 (1.11–1.77) 0.005*
Hemoglobin (g/dL) 1.04 (0.90–1.22) 0.54
Multivariable-adjusted logistic regression models were adjusted for: age,
gender, albumin, hemoglobin, DM, hs-CRP and immunophenotype group. The
immunophenotype groups were constructed as a categorical variable based
on the median-split of the absolute number of CD8+ TEMRA cells and
intermediate monocyte number (MonINT), with the Low MonINT Low CD8+
TEMRA group as the reference group. The results were expressed as odds ratio
(OR), 95% confidence interval (CI)
*P value < 0.05
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For example, unstable atherosclerotic plaques show a
10-fold increase in their T cell content [33]. In patients
with chronic kidney disease without dialysis, CD8+CD57
+ T cell (similar to TEMRA cell) fraction positively associ-
ates with arterial stiffness [34]. Terminally differentiated T
cells are highly proinflammatory and may produce mul-
tiple cytokines [35]. In addition, TEM and TEMRA cells ex-
press high level of CX3CR1, a chemokine receptor allows
T cells to bind to activated endothelial cells through frac-
talkine [36, 37] and subsequently cause endothelial injury.
Recently, an interesting study [38] demonstrated less
immunosenescence in ESRD patients received peritoneal
dialysis when compared to hemodialysis. Surprisingly, pa-
tients received peritoneal dialysis had more acute rejection
events after renal transplantation. As a result, accelerated
immunosenescence might be harmful for cardiovascular
health in dialysis patients but after transplantation it might
be associated with better graft survival.
Our study also found that intermediate and non-classical
monocytes are both significantly increased in ESRD. These
monocytes are key players in atherosclerosis and previous
studies have provided ample evidence of their significant
predictive value for CAD and CVD in both the general
population as well as renal failure [39–41]. Intermediate
monocytes exhibit senescence features because they have
shorter telomere compared to classical monocytes and have
higher expression of β-galactosidase [42]. Similar to termin-
ally differentiated T cells, intermediate monocytes express
both high levels of CCR2 and CX3CR1 [43] and thus are
preferentially recruited to the vascular endothelium. In our
analysis, ESRD patients exhibit a dramatic increase in these
cells when compared to the healthy individuals. Patients
with longer dialysis vintage also exhibit higher percentage
of intermediate monocytes in their blood.
In humans, CMV virus infection is an important driver
of T cell senescence [44] and we have recently found that
level of CMV-IgG also positively associated with advanced
differentiation of T cells in ESRD patients [45]. Since the
iESRD participants are more than 99% CMV seropositive,
the enhanced aging-related immune changes we observed
is not due to CMV infection per se; but host factors might
have modulated CMV-specific immunity. By correlation
analyses, dialysis vintage was associated with both TEMRA
cells and intermediate monocytes independent of age. The
result strongly supports the hypothesis that the duration
of renal failure (thus dialysis vintage) may determine the
degree of immunosenescence. In addition, there was a sta-
tistically significant association between uremic toxin
p-cresyl sulfate levels with CD8+ TEMRA cells. Although
uremic toxin levels did not correlate with monocyte differ-
entiation, one explanation is that one-time, cross-sectional
measurement of uremic toxins may not completely cap-
ture the complete exposure of uremic milieu. It is import-
ant to recognize that the immunosenescent T cell
phenotype also does not normalize after successful renal
transplantation despite a rapid reduction of uremic toxins
[46]. As a result, effects of uremic toxin on immunosenes-
cence might not be reversible by reducing uremic toxin
levels.
Our study has several limitations. First, because this is
a cross-sectional observational study, the causality be-
tween aging-related immune changes and cardiovascular
disease cannot be established. Secondly, since the study
population is composed of 99% CMV seropositive
Taiwanese, it is not known if the findings can be extrap-
olated to CMV seronegative ESRD patients and to other
racial groups. Finally, T cells and monocytes may exhibit
aging-related changes in their effector functions that are
not reflected by phenotypic changes. In addition,
because regulatory T cell differentiation is also affected
by renal failure [47], an important direction of further
research is to investigate the effects of uremia on regula-
tory T cells and effector T cells separately.
Conclusions
ESRD patients exhibit accelerated immunosenescence in
both T lymphocyte and monocyte compartment and
these changes are positively related to inflammation and
cardiovascular morbidities. Chronic exposure to the
uremic milieu may directly contribute to these immune
changes. ESRD may be used as a disease model in the
future for investigating how immunosenescence medi-
ates inflammation and vascular health.
Additional file
Additional file 1: Table S1. Relationships between dialysis vintage and
immune cell subsets using tertiles of dialysis vintage, least squares
regression and robust regression. Table S2. Numbers of age-related
immune cells correlate with cardiovascular risk factors and systemic
Table 5 Correlations between uremic toxin levels with levels of CD8+ TEMRA cells
Cell subset p-cresyl sulfate (μg/ml) Indoxyl sulfate (μg/ml)
Correlation Coeff. P value Correlation Coeff. P value
CD8+ TEMRA (percent CD8+) 0.22 0.027* −0.01 0.97
CD8+ TEMRA (cell number) 0.22 0.029* −0.02 0.83
*P value < 0.05
Spearman’s correlation test was performed to analyze the relationships between TEMRA cell and uremic toxin levels. Positive relationships were found between
p-cresyl sulfate and CD8+ TEMRA cells
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inflammation in ESRD patients. Table S3. Comparisons of circulatory T
cell and monocyte subset cell numbers between ESRD patients with and
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immunosenescence. Table S5. Logistic regression model for coronary
artery disease and cardiovascular disease using subset percentage to
characterize the combinatorial immunophenotype. Figure S1. Represen-
tative staining of lymphocytes and monocytes. Figure S2. Correlogram
of immune cell subsets among healthy donors and ESRD patients.
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